Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001450
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage IIIIV and Relapsed NSCLC
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage IIIIV and Relapsed NSCLC
Status:
COMPLETED
Status Verified Date:
1999-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II study of paclitaxel Taxol R administered as a 96-hour 4 day continuous infusion followed by a bolus of cisplatin for previously untreated patients with stage IIIIV or relapsed non-small cell lung cancer NSCLC The goal of this phase II study is to determine the response rate of this infusional paclitaxel and bolus cisplatin regimen in patients with advanced NSCLC
Detailed Description:
This is a Phase II study of paclitaxel Taxol R administered as a 96-hour 4 day continuous infusion followed by a bolus of cisplatin for previously untreated patients with stage IIIIV or relapsed non-small cell lung cancer NSCLC The goal of this phase II study is to determine the response rate of this infusional paclitaxel and bolus cisplatin regimen in patients with advanced NSCLC In addition the plasma levels of paclitaxel will be measured and the in vitro paclitaxel chemosensitivity of the tumor cells from as many patients as possible will be determined This will allow further study of the relationship between in vitro drug sensitivity achievable plasma concentrations of paclitaxel and patients response to therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 95-C-0198 | None | None | None |